A 24-Month Prospective Observational Cohort Study Evaluating Oral Systemic Therapies in the Management of Adult Patients with Atopic Dermatitis in REAL-World Practice (AD-REAL)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50366
• EU PAS number:
  EUPAS37841
• Study ID:
  50366
• Official title and acronym:
  A 24-Month Prospective Observational Cohort Study Evaluating Oral Systemic Therapies in the Management of Adult Patients with Atopic Dermatitis in REAL-World Practice (AD-REAL)
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  Spain

  United Kingdom
• Study description:
  Due to the limited data available on current clinical practice and new treatments entering the market, the study aims to describe treatment patterns of baricitinib and other oral systemic treatments. Therefore, the primary objective of this study is to report descriptively the proportion of patients with all-cause treatment discontinuation at Week 24 after initiation of a new oral systemic treatment at baseline for the baricitinib cohort and the all other oral systemic treatment cohort.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Syneos Health

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 05/11/2020

Study start date

Planned: 07/05/2021

Actual: 15/12/2021

Date of final study report

Planned: 30/09/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable